Depression, Anxiety, and Type 1 Diabetes: What Real-World Data Reveals About a Hidden Risk Factor
For patients with type 1 diabetes (T1D), managing blood sugar is already a constant, demanding task. What happens to that management when a patient also develops depression or anxiety? Surprisingly, real-world evidence on this question has been limited, largely because the data needed to answer it doesn’t live in any one place. We set out […]
What Happens When Patients Stop Taking Antidepressants? Here’s What Real-World Data Shows
Antidepressant use in the U.S. has been climbing for years, and so has the length of time patients stay on these medications. That trend recently became a flashpoint: In May 2026, HHS Secretary Robert F. Kennedy Jr. announced a plan aimed at curbing what he describes as a “dependency crisis driven by overmedicalization,” with new […]
AI + Real-World Data: What the Next Five Years Look Like for Pharma
In the final episode of Real-World Data After Dark season 2, host Daniel Chancellor is joined by Norstella’s Kris Kaneta, Chief Product & Innovation Officer, and Ted Search, Chief Real-World Data & Analytics Officer, to explore what’s next for real-world data, artificial intelligence, and healthcare analytics. Looking beyond today’s AI capabilities, the conversation examines how […]
Stop Flying Blind. Start Targeting with Greater Precision.
NorstellaLinQ explores how integrated real-world data and AI-powered analytics help pharmaceutical commercial teams identify high-value patients, understand prescriber behavior and uncover emerging market opportunities. By connecting claims, structured and unstructured EHR data, laboratory results, social determinants of health (SDOH) and mortality data into a single clinically validated asset, NorstellaLinQ delivers the insights needed to improve […]
Unstructured EHR Data Unmatched Clinical Insights
Norstella transforms unstructured physician notes into longitudinal, analytics-ready data that reveals insights traditional healthcare datasets miss. By combining AI, data curation, and clinical expertise, Norstella helps pharmaceutical teams better understand patient journeys, identify hard-to-find patient populations, optimize HCP engagement and make smarter commercial decisions. Powered by NorstellaLinQ, these insights connect real-time EHR data, claims, lab […]
Find the Right Patient Before the Competition Does
Traditional commercial targeting relies on historical claims and broad provider segments. NorstellaLinQ changes the equation by combining AI-curated clinical data, real-world patient journeys, predictive analytics, and near real-time clinical signals to identify more patients, engage providers earlier, predict what’s next, and coordinate commercial teams around the highest-value opportunities. In this infographic, find out how NorstellaLinQ can help […]
Finding the Right Patients Faster: AI and Real-World Data in Practice
Artificial intelligence is reshaping how life sciences organizations generate evidence, identify patients and make critical decisions—but only when it’s built on trusted, explainable data. In this episode of Real-World Data After Dark, Daniel Chancellor is joined by Norstella’s Kris Kaneta and Ted Search to discuss where AI can create the greatest impact across the pharmaceutical […]
Busting Real-World Data and AI Myths
Artificial intelligence is transforming how life sciences organizations unlock the full value of real-world data—but success depends on more than AI alone. In this episode of Real-World Data After Dark, Daniel Chancellor is joined by Kris Kaneta, Chief Product & Innovation Officer at Norstella, and Ted Search, Chief Real-World Data & Analytics Officer at Norstella, […]
The Hidden Obesity Population: Why Diagnosis Codes Fail Pharma, Payers, and Patients
More than 60% of clinically obese patients cannot be identified using diagnosis codes alone. For manufacturers, payers, and providers, that means prior authorizations fail, commercial opportunity is underestimated, and real-world evidence built on ICD-10 codes alone systematically miss eligible patients. Anti-obesity medications are the most consequential pharmacological development in obesity treatment in a generation. Semaglutide […]
From Data Access to Evidence Usability: Connecting Payer Policy, Real-World Data, and Clinical Context to Close the Evidence Gap
Real-world data has never been more abundant, but data alone doesn’t tell the full patient story. In this episode of tHEORetically Speaking, Becky Hollenberg, Senior Real-World Data Strategy Lead at Norstella, explores why connecting claims, electronic medical records (EMRs), clinical notes, laboratory data, and payer policy information is essential to generating meaningful real-world evidence. The conversation […]
